Actively Recruiting
The Healthy Elderly Longevity Cohort
Led by Scripps Translational Science Institute · Updated on 2025-01-17
5000
Participants Needed
1
Research Sites
1169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
With the completion of the human genome project, investigators can now explore new questions in human biology. Previously human genetics focused on highly penetrant, Mendelian traits; however, now rare and common variants can be discovered that affect "common" diseases that have multi-gene architecture with variable penetrance such as breast cancer, diabetes mellitus, and coronary artery disease. This change took place because investigators now have the tools to illuminate the whole genome at once to discover the genetic variants responsible for different disease phenotypes through statistical differences between populations. Besides disease phenotypes, health can be considered a human phenotype that can be studied. Health is not merely the absence of disease but may be viewed as a dynamic ongoing interplay between the environment and the genome to maintain homeostasis. Individuals often attempt to optimize environmental conditions according to ones genome to maximize their health. All individuals possess potentially beneficial and harmful variants depending on the environment. How this dynamic interplay occurs between the genome and environment requires understanding the boundary conditions of the genetic architecture of health and disease and then modeling the system to simulate the observed data. The aging process also affects health. Aging involves a loss of the normal coping responses to internal and external environmental stressors or signals. Investigators now have the tools to uncover from the bottom up the mechanisms involved in maintaining the ability to overcome environmental conditions that can affect health. Against this genomic breakthrough of whole genome association studies, the demographics in the United States are quickly changing. The older population (age \> 65 years) in 2030 is projected to be twice as large as in 2000 representing nearly 20 percent of the total US population. The first baby boomers turn 65 in 2011 and will challenge all facets of health care in the coming decades. The demographic changes underscore the need to understand the mechanisms that promote health and disease in this cohort. Genomic discoveries will help individuals and may reduce medical costs and benefit society. In summary, the objective of this study is to obtain blood and/or saliva samples in order to help model health and disease phenotypes through population genomics. The blood and/or saliva samples may allow for participants' entire genomes to be sequenced if such comprehensive analysis becomes feasible and economical.
CONDITIONS
Official Title
The Healthy Elderly Longevity Cohort
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 80 years or older
- Eligible for blood draw and/or saliva collection
- Be reliable, cooperative and willing to comply with all protocol-specified procedures
- Able to understand and grant informed consent
- Be healthy or have mild medical conditions associated with normal aging, including well-controlled hypertension (no more than 3 medications), osteoporosis, osteopenia, osteoarthritis, benign prostatic hypertrophy, cataracts, glaucoma, macular degeneration, dyslipidemia, hypothyroidism, or pre-diabetes/impaired fasting glucose (fasting blood glucose 100-126 mg/dL, if known)
You will not qualify if you...
- Younger than 80 years old
- Previously enrolled in The Scripps Genebank Healthy Elderly Cohort
- Treatment with any investigational agents or devices within 30 days before enrollment
- History or current diagnosis of significant chronic conditions, including any cancer (except basal or squamous cell skin cancer), coronary artery disease/myocardial infarction, stroke/transient ischemic attack, deep vein thrombosis/pulmonary embolus, chronic renal disease/hemodialysis, significant autoimmune/inflammatory conditions (e.g., rheumatoid arthritis, lupus, Crohn's), Alzheimer's or Parkinson's disease, diabetes with hemoglobin A1C > 6.5% or fasting glucose >126 mg/dL or treated with diabetic medications/insulin if known, aortic or cerebral aneurysm
- Regular use of medications such as oral chemotherapeutic agents (e.g., tamoxifen, doxorubicin), anti-platelet agents excluding aspirin (e.g., clopidogrel), cholinesterase inhibitors for Alzheimer's (e.g., donepezil), or insulin
- Significant medical conditions that may interfere with study participation or confound results, as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Scripps Translational Science Institute
La Jolla, California, United States, 92037
Actively Recruiting
Research Team
S
Sarah Topol, BS
CONTACT
E
Emily Spencer, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here